Skip to content

Perioperative use of pregabaline in mastectomies

Pregabaline as attenuator of Acute and Chronic Post-Operative Pain in mastectomies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-555xm5
Enrollment
Unknown
Registered
2018-06-15
Start date
2014-01-09
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group A: Twenty female patients (20) submitted to mastectomies received pregabalin capsule 150 mg orally the night before surgery and continued for 14 days after 12 /12 hours. Group B: Twenty-five fem
Drug
E01.370.600.550.324

Sponsors

Universidade Federal de Santa Maria
Lead Sponsor
Universidade Federal de Santa Maria
Collaborator

Eligibility

Sex/Gender
Female
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Women's volunteers; scheduled for mastectomies; between 20 and 65 years; ASA II and III; without renal and hepatic comorbidities.

Exclusion criteria

Exclusion criteria: Women's Volunteers; scheduled for mastectomies; with hepatic and / or renal comorbidities; with BMI greater than 40; with low cognitive degree; not agreeing to participate in the study.

Design outcomes

Primary

MeasureTime frame
Reduction of chronic postoperative pain in mastectomies with the perioperative use of pregabalin, verified by the Mann-Whitney test, based on a variation of at least 5%.;There was no reduction of postoperative chronic pain in patients who used pregabalin, both verified by Mann-Whitney test, based on a variation of at least 5%.

Secondary

MeasureTime frame
Reduction of acute postoperative pain in mastectomies after the use of perioperative pregabalin verified by the Mann-Whitney test, based on a variation of at least 5%.;There was a reduction in postoperative acute pain evaluated by the lower consumption of morphine in the first 24 hours postoperatively, based on a variation of at least 5%.

Countries

Brazil

Contacts

Public ContactMiriam Menezes

Universidade Federal de Santa Maria

miriamsmenezes@gmail.com+55 55 999717728

Outcome results

None listed

Source: REBEC (via WHO ICTRP)